Cosmetic Surgery Center EBITDA Valuation Multiples
Lower middle market aesthetic practices typically trade at 3.5x–6x EBITDA. Learn what drives pricing, who the buyers are, and how to maximize your exit value.
Cosmetic surgery centers in the $1M–$5M revenue range typically sell at 3.5x–6x EBITDA, with pricing driven by surgeon key-man risk, procedure mix diversification, recurring non-surgical revenue, and clean malpractice history. PE-backed consolidators and SBA-financed individual buyers dominate this segment, with deal structures often requiring MSO compliance and physician earnouts.
Cosmetic Surgery Center EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or High-Risk | $150K–$400K | 3.5x–4.0x | Single-surgeon dependency, unresolved malpractice, or revenue concentration in surgical cases only. Minimal recurring non-surgical revenue. Significant buyer discount applied. |
| Average Quality | $400K–$700K | 4.0x–4.75x | Some procedure diversification, moderate key-man risk, associate staff present but untested. Clean financials with minor add-backs. SBA-eligible for qualified buyers. |
| Above Average | $700K–$1.2M | 4.75x–5.5x | Mix of surgical and repeat non-surgical revenue, associate physician in place, AAAHC accreditation, documented systems. Attractive to PE add-on platforms and strategic acquirers. |
| Premium Platform | $1.2M–$2M+ | 5.5x–6.0x | Multi-surgeon model, strong Botox and filler patient base, minimal key-man risk, clean regulatory history. PE platform target with rollover equity and earnout structures common. |
What Drives Cosmetic Surgery Center Multiples
Physician Key-Man Dependency
High Negative impactPractices where 80%+ of revenue ties to the selling surgeon face steep discounts. Buyers demand associate physicians or NPs who can sustain revenue post-transition before closing.
Recurring Non-Surgical Revenue
High Positive impactA loyal injectable and laser treatment patient base signals predictable cash flow. Repeat Botox and filler patients significantly increase perceived revenue sustainability and buyer confidence.
Malpractice and Regulatory History
High Negative impactUnresolved claims, board complaints, or licensing issues can kill deals or trigger escrow holdbacks. Buyers require tail coverage review and clean NPDB records before proceeding.
Accreditation and Facility Status
Moderate Positive impactAAAHC or JCAHO-accredited in-office surgical suites command premium multiples. Accreditation signals compliance maturity, reduces buyer risk, and creates meaningful barriers to entry for competitors.
MSO/PC Structure Compliance
Moderate Positive impactA properly established Management Services Organization separating the business from the medical PC simplifies deal structuring, satisfies CPOM requirements, and broadens the eligible buyer pool significantly.
Recent Market Trends
PE-backed aesthetic consolidators have driven multiple expansion in this sector through 2022–2024, pushing quality assets toward 5.5x–6x EBITDA. Rising interest rates have tempered SBA deal activity slightly, but demand for accredited cosmetic surgery centers with diversified revenue remains strong. Buyers increasingly require associate physician retention agreements and earnouts tied to 24-month post-close revenue performance.
Sample Cosmetic Surgery Center Transactions
Two-surgeon cosmetic center in Sun Belt market, strong Botox/filler recurring base, AAAHC-accredited, clean malpractice history, associate retained post-close.
$1.1M
EBITDA
5.5x
Multiple
$6.05M
Price
Single-surgeon facial surgery practice with moderate key-man risk, transitioning to MSO structure, SBA-financed deal with 18-month physician earnout.
$550K
EBITDA
4.25x
Multiple
$2.34M
Price
Multi-location cosmetic surgery and med-spa hybrid, PE add-on acquisition, rollover equity included, strong non-surgical revenue representing 45% of total.
$1.8M
EBITDA
5.75x
Multiple
$10.35M
Price
EBITDA Valuation Estimator
Get your Cosmetic Surgery Center business value range instantly
Industry: Cosmetic Surgery Center · Multiples based on 4.0x–4.75x (Average Quality)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect when selling my cosmetic surgery center?
Most lower middle market cosmetic surgery centers sell at 3.5x–6x EBITDA. Premium multiples require associate physicians, diversified procedure revenue, clean malpractice history, and AAAHC accreditation.
How does physician key-man risk affect my practice valuation?
If you personally generate 80%+ of revenue, buyers will discount heavily or require a long earnout. Hiring an associate physician before going to market is the single biggest value lever available.
Can I use an SBA loan to buy a cosmetic surgery center?
Yes. SBA 7(a) loans are commonly used for acquisitions under $5M. Buyers typically finance 70–80% via SBA with a seller note covering the balance, contingent on a physician transition period.
What deal structure is most common in cosmetic surgery center acquisitions?
Asset purchases using an MSO structure are most common to comply with state CPOM laws. Stock purchases with seller rollover equity and 2–3 year earnouts are typical in PE-backed transactions.
More Cosmetic Surgery Center Guides
Find Cosmetic Surgery Center businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required